Nuo Therapeutics, Inc. Announces Amended and Restated Loan and Security Agreement with Significant New Funding and Warrant Issuances
Key Points for Investors
- Amended and Restated Loan Agreement: On May 29, 2026, Nuo Therapeutics, Inc. entered into an Amended and Restated Loan and Security Agreement (the “Interim Loan Agreement”) with five lenders, increasing the total loan commitment by \$400,000 to a new aggregate principal amount of up to \$2.0 million.
- Funding Structure: The funding under the new agreement consists of three tranches:
- \$1,000,000 previously funded on January 23, 2026 (Initial Closing)
- \$675,000 advanced at the May 29, 2026 closing (Interim Funding)
- \$325,000 to be advanced on September 30, 2026, subject to company request (Second Funding)
- Interest Rate: The outstanding principal amounts will accrue interest at a significant rate of 12% per annum, effective from April 1, 2026. In no event will the interest rate exceed the maximum rate permitted by law.
- Interest Payment Structure: Critically, accrued interest is not payable in cash. It is to be paid solely by the issuance of “Interest Warrants” to the lenders, which may affect dilution and future share supply.
- Issuance and Cancellation of Warrants: At the closing of the Interim Funding, Nuo Therapeutics issued new warrants to purchase shares of common stock to each lender. These warrants are partially subject to vesting provisions. Simultaneously, certain warrants issued during the Initial Funding were canceled, and the company agreed to issue more warrants as payment for accrued interest.
- Warrant Terms: Each warrant entitles the holder to purchase common stock at an exercise price of \$1.50 per share. The number of shares issuable upon exercise is calculated using the same \$1.50 price. The warrants contain provisions for cash and cashless exercise, and are subject to anti-dilution and adjustment clauses for events such as dividends, distributions, and fundamental transactions (e.g., merger, sale of assets, or reclassification).
- Exemption from Registration: The warrants and underlying shares are sold under the exemption from registration provided by Section 4(a)(2) of the Securities Act. They are restricted securities and may not be offered or sold in the U.S. absent registration or an applicable exemption.
- Emerging Growth Company Status: Nuo Therapeutics is not considered an emerging growth company under relevant SEC definitions.
Potentially Price-Sensitive Information for Shareholders
- Dilution Risk: The issuance of a significant number of new warrants—both as part of the funding and as payment for interest—introduces the potential for future dilution, which may impact the value of existing shares if exercised.
- High Interest Rate and Non-Cash Interest Payments: The company is borrowing at a high 12% interest rate, and will pay all interest in the form of warrants rather than cash. This is a clear sign that Nuo Therapeutics is seeking to conserve cash, but it also means the share count could increase substantially over time.
- Loan Prepayment Triggers and Mandatory Repayment: The loan agreement contains provisions that may trigger mandatory prepayment, such as if the company enters an equity financing or a change of control event occurs. In these cases, lenders will be repaid in cash and will also receive additional warrants for accrued interest.
- Warrant Terms Could Affect Future Share Price: The warrants have anti-dilution and adjustment clauses, meaning their value and the number of shares issuable upon exercise could change in the event of stock splits, dividends, or other capital structure changes.
- Restricted Securities: The new securities are not registered and are subject to transfer restrictions, potentially affecting liquidity for warrant holders and the market for the company’s common stock.
Detailed Summary
Nuo Therapeutics, Inc. has secured a new round of funding through an Amended and Restated Loan and Security Agreement, increasing its debt capacity to \$2 million. This move provides much-needed liquidity but comes at a high cost, with a 12% annual interest rate and the issuance of a large number of new warrants to the lenders. The company is using warrants to pay interest, avoiding cash payments but increasing the risk of dilution for existing shareholders.
The company will issue multiple types of warrants, including Commitment Supplemental Warrants, Origination Interim Warrants, Capital Interim Warrants, Restated Second Warrants, Prepayment Restated Warrants, and Interest Warrants. All such securities are unregistered and restricted, but their exercise could increase the company’s outstanding share count significantly.
The Interim Loan Agreement is structured to provide flexibility, with tranches of funding and mandatory prepayment provisions upon certain corporate events. However, the combination of high-interest costs and the payment of interest with equity-linked securities suggests that Nuo Therapeutics is currently unable or unwilling to pay cash interest, which could be a concern for risk-averse investors.
Importantly, the terms of the warrants include cashless exercise options, anti-dilution protections, and adjustment mechanisms, which could further impact the capital structure and share price depending on future corporate actions.
For existing shareholders, the key issues are the risk of dilution, the company’s reliance on non-cash forms of interest payment, and the potential for further changes to the capital structure that could arise from future events under the loan agreement.
Disclaimer
This article is provided for informational purposes only and does not constitute investment advice. Investors are encouraged to review the full Form 8-K and exhibits filed by Nuo Therapeutics, Inc. with the SEC and to consult with their financial advisors before making investment decisions. The information above is as of the date of the original SEC filing and may be subject to change.
